Entheon Biomedical Lists on OTCQB Venture Market
Vancouver, British Columbia--(Newsfile Corp. - May 5, 2021) - Entheon Biomedical Corp. (CSE: ENBI) (OTCQB: ENTBF) (FSE: "1XU1") ("Entheon" or the "Company"), a biotechnology company focused on developing psychedelic medicines to treat addiction, is pleased to announce that it has been approved for trading on the OTCQB Venture Market ("OTCQB") effective May 5, 2021. "We are thrilled to be up-listing on to the OTCQB, which will allow for greater engagement with our U.S. investor base. As we...
2021-05-05 10:30 AM EDT
Entheon Biomedical Corp. Launches HaluGen's Psychedelics Genetic Test
Vancouver, British Columbia--(Newsfile Corp. - April 6, 2021) - Entheon Biomedical Corp. (CSE: ENBI) (FSE: 1XU1) ("Entheon" or the "Company"), a biotechnology company focused on developing psychedelic medicines to treat addiction, announces the launch of the industry's first Psychedelics Genetic Test Kit, developed by wholly-owned subsidiary, HaluGen Life Sciences Inc. ("HaluGen"), and that it is now available for sale within Canada. HaluGen's psychedelic pre-screening platform and DNA...
2021-04-06 8:30 AM EDT
Entheon Biomedical Announces Nancy Maher, Special Advisor of Data Science and Regulatory Affairs
Vancouver, British Columbia--(Newsfile Corp. - March 3, 2021) - Entheon Biomedical Corp. (CSE: ENBI) (OTC Pink: ENTBF) (FSE: 1XU1) ("Entheon" or the "Company"), a biotechnology company focused on developing psychedelic medicines to treat addiction, is pleased to announce Nancy Maher as Special Advisor of Data Science and Regulatory Affairs, providing expertise on the development of the Company's data strategy design, study design and advise on regulatory relationships and data strategy. Ms....
2021-03-03 8:30 AM EST
Entheon Biomedical Corp. Provides Update on Subsidiary, HaluGen Life Sciences
Vancouver, British Columbia--(Newsfile Corp. - February 24, 2021) - Entheon Biomedical Corp. (CSE: ENBI) (FSE: 1XU1) ("Entheon" or the "Company"), a biotechnology company focused on developing psychedelic medicines to treat addiction, provides a production update on HaluGen Life Sciences Inc. ("HaluGen"), a wholly-owned subsidiary of Entheon, which is in the business of developing and commercializing a genetic test designed to identify specific DNA biomarkers in order to gauge the risk and...
2021-02-24 8:30 AM EST
Entheon Biomedical Announces Ethics Approval for In Vivo DMT Study
Vancouver, British Columbia--(Newsfile Corp. - February 22, 2021) - Entheon Biomedical Corp. (CSE: ENBI) (OTC: ENTBF) (FSE: 1XU1) ("Entheon" or the "Company"), a biotechnology company focused on developing psychedelic medicines to treat addiction, announced ethics approval for an upcoming pre-clinical study to be conducted by the clinical research organization, Science in Action, an Israeli-based lab specializing in pre-clinical in vivo and in vitro R&D services. Science in Action has...
2021-02-22 8:30 AM EST
Entheon Biomedical Hires Chief Business Officer; Senior Pharma Executive Dr. Brian Jahns to Oversee Business Development
Vancouver, British Columbia--(Newsfile Corp. - February 16, 2021) - Entheon Biomedical Corp. (CSE: ENBI) (OTC Pink: ENTBF) (FSE: 1XU1) ("Entheon" or the "Company"), a biotechnology company focused on developing psychedelic medicines to treat addiction, is pleased to announce the appointment of Dr. Brian Jahns to the role of Chief Business Officer. Dr. Jahns brings more than 20 years of business leadership and biopharmaceutical expertise to his role in overseeing the overall business...
2021-02-16 8:30 AM EST
Entheon Biomedical Hires ClearTV Executive as VP of Digital Experience Entertainment Veteran Jonna Birgans to Oversee Digital and VR Content Development
Vancouver, British Columbia--(Newsfile Corp. - February 4, 2021) - Entheon Biomedical Corp. (CSE: ENBI) (OTC PINK: ENTBF) (FSE: 1XU1) ("Entheon" or the "Company"), a biotechnology company focused on developing psychedelic medicines to treat addiction, is pleased to announce the appointment of Jonna Birgans, a highly experienced media executive and producer, as Vice President of Digital Experience. Mrs. Birgans' significant depth of experience spans wide across the media and entertainment...
2021-02-04 8:30 AM EST
Entheon Biomedical Provides Update on Centre for Human Drug Research License Amendments
Vancouver, British Columbia--(Newsfile Corp. - February 2, 2021) - Entheon Biomedical Corp. (CSE: ENBI) (OTC Pink: ENTBF) (FSE: 1XU1) ("Entheon" or the "Company"), a biotechnology company focused on developing psychedelic medicines to treat addiction, provides an update on license amendments issued to its clinical research organization, The Centre for Human Drug Research (CHDR). Entheon confirms that the CHDR, the Company's Netherlands-based partner clinical research organization, has...
2021-02-02 8:30 AM EST
Entheon Biomedical to be Included in First North American Psychedelic ETF
Vancouver, British Columbia--(Newsfile Corp. - January 22, 2021) - Entheon Biomedical Corp. (CSE: ENBI) (OTC Pink: ENTBF) (FSE: 1XU1) ("Entheon" or the "Company"), a biotechnology company focused on developing psychedelic medicines to treat addiction, is pleased to announce its inclusion in the Horizon North American Psychedelic ETF, the first ever psychedelic ETF of its kind. The new ETF is expected to start trading January 26, 2021 under the symbol "PYSK" on the NEO exchange. The...
2021-01-22 8:30 AM EST
Entheon Biomedical Partners with Divergence Neuro Technologies Inc. for Predictive Biomarker Platform Development
Vancouver, British Columbia--(Newsfile Corp. - January 19, 2021) - Entheon Biomedical Corp. (CSE: ENBI) (FSE: 1XU1) (OTC Pink: ENTBF) ("Entheon" or the "Company"), a biotechnology company focused on developing psychedelic medicines to treat addiction, announced a partnership with Divergence Neuro Technologies Inc. ("Divergence"), a company focused on the research and development of a data-driven, cloud-based neuro platform based on electroencephalogram ("EEG") analysis and machine learning,...
2021-01-19 8:30 AM EST
Entheon Biomedical Corp. Announces Acquisition of HaluGen Life Sciences Inc.
Vancouver, British Columbia--(Newsfile Corp. - January 14, 2021) - Entheon Biomedical Corp. (CSE: ENBI) (FSE: 1XU1) ("Entheon" or the "Company") is pleased to announce that the Company completed its acquisition of HaluGen Life Sciences Inc. ("HaluGen"), a biotech company in the business of developing and commercializing a pre-screening test to identify genetic markers predictive of an individual's reaction to hallucinogenic drugs. The Company acquired 100% of the issued and outstanding common...
2021-01-14 8:30 AM EST
Entheon Biomedical Engages Star Finance GmbH for Investor Relations
Vancouver, British Columbia--(Newsfile Corp. - January 12, 2021) - Entheon Biomedical Corp. (CSE: ENBI) (FSE: 1XU1) ("Entheon" or the "Company"), a biotechnology company focused on developing psychedelic medicines to treat addiction, announces that it has entered into a consulting agreement (the "Agreement") with Star Finance GmbH ("Star Finance"), a Swiss-based company, to provide European investor relations services. Star Finance has offices in Steinhausen, Switzerland, and Cologne,...
2021-01-12 4:39 PM EST
Entheon Biomedical Engages World Renowned Media Personality DJ Skee, AKA Scott Keeney, as Media Advisor
Vancouver, British Columbia--(Newsfile Corp. - January 11, 2021) - Entheon Biomedical Corp. (CSE: ENBI) (FSE: 1XU1) ("Entheon" or the "Company"), a biotechnology company focused on developing psychedelic medicines to treat addiction, is pleased to announce that it has engaged Mr. Scott Keeney, to serve as a media advisor. In his role, Mr. Keeney will work directly with the CEO of the Company, Timothy Ko, to develop multimedia campaigns and experiences specifically designed to define Entheon's...
2021-01-11 8:30 AM EST
Entheon Biomedical Announces Investment and Business Arrangement with Heading Health LLC
Vancouver, British Columbia--(Newsfile Corp. - January 4, 2021) - Entheon Biomedical Corp. (CSE: ENBI) (FSE: 1XU1) ("Entheon" or the "Company"), a biotechnology company focused on developing psychedelic medicines to treat addiction, is announcing a business arrangement with, and a strategic investment in, Heading Health, LLC ("Heading Health"), a psychiatric clinic platform focused on the administration of psychedelic-assisted therapy to treat mental health disorders. Entheon has participated...
2021-01-04 8:30 AM EST
Entheon Biomedical Closes Private Placement
Vancouver, British Columbia--(Newsfile Corp. - December 25, 2020) - Entheon Biomedical Corp. (CSE: ENBI) (FSE: 1XU1) ("Entheon" or the "Company") announces that it has closed a non-brokered private placement financing for total gross proceeds of CAD $3,174,374.25 (the "Placement"). The majority of the Placement was subscribed for by strategic investors. The Company has allotted and issued 4,232,499 units (the "Units") at a price of CAD $0.75 per Unit. Each Unit is comprised of one common...
2020-12-25 8:30 AM EST
Entheon Biomedical Announces Private Placement
Vancouver, British Columbia--(Newsfile Corp. - December 18, 2020) - Entheon Biomedical Corp. (CSE: ENBI) (FSE: 1XU1) ("Entheon" or the "Company") announces that it is proceeding with a fully allocated, non-brokered private placement financing of 4,266,997 Units (the "Units") at a price of CDN$0.75 per Unit for gross proceeds of CDN$3,200,247.75 (the "Placement"). This placement is fully subscribed by strategic investors and is expected to close on December 23rd. Each Unit will consist of one...
2020-12-18 5:16 PM EST
Entheon Biomedical Announces DMT Drug Supply Agreement with Psygen Labs Inc. Completion of Initial DMT Research Drug Batch and Exercise of Warrants
Vancouver, British Columbia--(Newsfile Corp. - December 9, 2020) - Entheon Biomedical Corp. (CSE: ENBI) (FSE: 1XU1) ("Entheon" or the "Company"), a biotechnology company focused on developing psychedelic medicines to treat addiction, announced it has entered into a drug-supply agreement (the "Agreement") with Psygen Labs Inc. ("Psygen"). Under the terms of the Agreement, Psygen will supply Entheon with non-GMP and GMP (good manufacturing practice) quality N,N-dimethyltryptamine drug...
2020-12-09 8:30 AM EST
Entheon Biomedical Announces Corporate Update Including Investment in Wonder Scientific
Vancouver, British Columbia--(Newsfile Corp. - December 4, 2020) - Entheon Biomedical Corp. (CSE: ENBI) (FSE: 1XU1) ("Entheon" or the "Company"), a biotechnology company focused on developing psychedelic medicines to treat addiction, announces a strategic investment in Wonder Scientific Inc. ("Wonder Scientific"). Wonder Scientific's team of University Researchers and Product Development experts create custom, naturally derived, active pharmaceutical ingredients (APIs) to supply the growing...
2020-12-04 8:30 AM EST
Entheon Biomedical Announces CRO Agreement with CHDR for Phase 1 Clinical Trial; Centre for Human Drug Research Led DMT Study to Start in 2021
Vancouver, British Columbia--(Newsfile Corp. - December 1, 2020) - Entheon Biomedical Corp. (CSE: ENBI) (FSE: 1XU1) ("Entheon" or the "Company"), a biotechnology company focused on developing psychedelic medicines to treat addiction, announced it has entered into a Clinical Study Agreement with the Contract Research Organization (CRO) Centre for Human Drug Research (CHDR) to conduct an early phase human clinical trial with DMT. CHDR is a Leiden, Netherlands-based contract research...
2020-12-01 8:30 AM EST
Entheon Biomedical to Begin Trading on the Frankfurt Exchange
Vancouver, British Columbia--(Newsfile Corp. - November 26, 2020) - Entheon Biomedical Corp. (CSE: ENBI) (FSE: 1XU1) ("Entheon" or the "Company"), a biotechnology company focused on developing psychedelic medicines to treat addiction, is pleased to announce that its shares have commenced trading on the Frankfurt Stock Exchange under the symbol "1XU1". The Frankfurt Stock Exchange is the world's tenth largest organized exchange-trading market in terms of turnover and dealings in securities....
2020-11-26 8:30 AM EST